The use of CrossMAb technology for the generation of bi- and multispecific antibodies

References

• Schaefer W, Volger HR, Lorenz S, Imhof-Jung S, Regula JT, Klein C, Molhoj M. Heavy and light chain pairing of bivalent quadroma and knobs-into-holes antibodies analyzed by uhr-esi-qtof mass spectrometry. MAbs 2016; 8(1):49-55; PMID:26496506; http://dx.doi.org/10.1080/19420862.2015.1111498
   PubMed Web of Science ®Google Scholar
• Klein C, Sustmann C, Thomas M, Stubenrauch K, Croasdale R, Schanzer J, Brinkmann U, Kettenberger H, Regula JT, Schaefer W. Progress in overcoming the chain association issue in bispecific heterodimeric igg antibodies. MAbs 2012; 4(6):653-63; PMID:22925968; http://dx.doi.org/10.4161/mabs.21379
   PubMed Web of Science ®Google Scholar
• Merchant AM, Zhu Z, Yuan JQ, Goddard A, Adams CW, Presta LG, Carter P. An efficient route to human bispecific igg. Nat Biotechnol 1998; 16(7):677-81; PMID:9661204; http://dx.doi.org/10.1038/nbt0798-677
   PubMed Web of Science ®Google Scholar
• Schaefer W, Regula JT, Bahner M, Schanzer J, Croasdale R, Durr H, Gassner C, Georges G, Kettenberger H, Imhof-Jung S, et al. Immunoglobulin domain crossover as a generic approach for the production of bispecific igg antibodies. Proc Natl Acad Sci U S A 2011; 108(27):11187-92; PMID:21690412; http://dx.doi.org/10.1073/pnas.1019002108
   PubMed Web of Science ®Google Scholar
• Dengl S, Wehmer M, Hesse F, Lipsmeier F, Popp O, Lang K. Aggregation and chemical modification of monoclonal antibodies under upstream processing conditions. Pharm Res 2013; 30(5):1380-99; PMID:23322133; http://dx.doi.org/10.1007/s11095-013-0977-8
   PubMed Web of Science ®Google Scholar
• Gu J, Yang J, Chang Q, Liu Z, Ghayur T. Identification of anti-egfr and anti-erbb3 dual variable domains immunoglobulin (dvd-ig) proteins with unique activities. PLoS One 2015; 10(5):e0124135; PMID:25997020; http://dx.doi.org/10.1371/journal.pone.0124135
   PubMedGoogle Scholar
• Correia I, Sung J, Burton R, Jakob CG, Carragher B, Ghayur T, Radziejewski C. The structure of dual-variable-domain immunoglobulin molecules alone and bound to antigen. MAbs 2013; 5(3):364-72; PMID:23572180; http://dx.doi.org/10.4161/mabs.24258
   PubMed Web of Science ®Google Scholar
• Jakob CG, Edalji R, Judge RA, DiGiammarino E, Li Y, Gu J, Ghayur T. Structure reveals function of the dual variable domain immunoglobulin (dvd-ig) molecule. MAbs 2013; 5(3):358-63; PMID:23549062; http://dx.doi.org/10.4161/mabs.23977
   PubMed Web of Science ®Google Scholar
• Wu C, Ying H, Grinnell C, Bryant S, Miller R, Clabbers A, Bose S, McCarthy D, Zhu RR, Santora L, Davis-Taber R, et al. Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin. Nat Biotechnol 2007; 25(11):1290-7; PMID:17934452; http://dx.doi.org/10.1038/nbt1345
   PubMed Web of Science ®Google Scholar
• Steinmetz A, Vallee F, Beil C, Lange C, Baurin N, Beninga J, Capdevila C, Corvey C, Dupuy A, Ferrari P, et al. Codv-ig, a universal bispecific tetravalent and multifunctional immunoglobulin format for medical applications. MAbs 2016 July; 8(5): 867—78; PMID:26984268; http://dx.doi.org/10.1080/19420862.2016.1162932
   PubMedGoogle Scholar
• Smith EJ, Olson K, Haber LJ, Varghese B, Duramad P, Tustian AD, Oyejide A, Kirshner JR, Canova L, Menon J, et al. A novel, native-format bispecific antibody triggering t-cell killing of b-cells is robustly active in mouse tumor models and cynomolgus monkeys. Sci Rep 2015; 5:17943; PMID:26659273; http://dx.doi.org/10.1038/srep17943
   PubMed Web of Science ®Google Scholar
• Fischer N, Elson G, Magistrelli G, Dheilly E, Fouque N, Laurendon A, Gueneau F, Ravn U, Depoisier JF, Moine V, et al. Exploiting light chains for the scalable generation and platform purification of native human bispecific igg. Nat Commun 2015; 6:6113; PMID:25672245; http://dx.doi.org/10.1038/ncomms7113
   PubMed Web of Science ®Google Scholar
• Sampei Z, Igawa T, Soeda T, Okuyama-Nishida Y, Moriyama C, Wakabayashi T, Tanaka E, Muto A, Kojima T, Kitazawa T, et al. Identification and multidimensional optimization of an asymmetric bispecific igg antibody mimicking the function of factor viii cofactor activity. PLoS One 2013; 8(2):e57479; PMID:23468998; http://dx.doi.org/10.1371/journal.pone.0057479
   PubMed Web of Science ®Google Scholar
• Kitazawa T, Igawa T, Sampei Z, Muto A, Kojima T, Soeda T, Yoshihashi K, Okuyama-Nishida Y, Saito H, Tsunoda H, et al. A bispecific antibody to factors ixa and x restores factor viii hemostatic activity in a hemophilia a model. Nat Med 2012; 18(10):1570-4; PMID:23023498; http://dx.doi.org/10.1038/nm.2942
   PubMed Web of Science ®Google Scholar
• Tustian AD, Endicott C, Adams B, Mattila J, Bak H. Development of purification processes for fully human bispecific antibodies based upon modification of protein a binding avidity. MAbs 2016; 8(4):828-38; PMID:26963837; http://dx.doi.org/10.1080/19420862.2016.1160192
   PubMed Web of Science ®Google Scholar
• Spiess C, Merchant M, Huang A, Zheng Z, Yang NY, Peng J, Ellerman D, Shatz W, Reilly D, Yansura DG, et al. Bispecific antibodies with natural architecture produced by co-culture of bacteria expressing two distinct half-antibodies. Nat Biotechnol 2013; 31(8):753-8; PMID:23831709; http://dx.doi.org/10.1038/nbt.2621
   PubMed Web of Science ®Google Scholar
• Labrijn AF, Meesters JI, de Goeij BE, van den Bremer ET, Neijssen J, van Kampen MD, Strumane K, Verploegen S, Kundu A, Gramer MJ, et al. Efficient generation of stable bispecific igg1 by controlled fab-arm exchange. Proc Natl Acad Sci U S A 2013; 110(13):5145-50; PMID:23479652; http://dx.doi.org/10.1073/pnas.1220145110
   PubMed Web of Science ®Google Scholar
• Spiess C, Bevers J, 3rd, Jackman J, Chiang N, Nakamura G, Dillon M, Liu H, Molina P, Elliott JM, Shatz W, et al. Development of a human igg4 bispecific antibody for dual targeting of interleukin-4 (il-4) and interleukin-13 (il-13) cytokines. J Biol Chem 2013; 288(37):26583-93; PMID:23880771; http://dx.doi.org/10.1074/jbc.M113.480483
   PubMed Web of Science ®Google Scholar
• Strop P, Ho WH, Boustany LM, Abdiche YN, Lindquist KC, Farias SE, Rickert M, Appah CT, Pascua E, Radcliffe T, et al. Generating bispecific human igg1 and igg2 antibodies from any antibody pair. J Mol Biol 2012; 420(3):204-19; PMID:22543237; http://dx.doi.org/10.1016/j.jmb.2012.04.020
   PubMed Web of Science ®Google Scholar
• Schaefer G, Haber L, Crocker LM, Shia S, Shao L, Dowbenko D, Totpal K, Wong A, Lee CV, Stawicki S, et al. A two-in-one antibody against her3 and egfr has superior inhibitory activity compared with monospecific antibodies. Cancer Cell 2011; 20(4):472-86; PMID:22014573; http://dx.doi.org/10.1016/j.ccr.2011.09.003
   PubMed Web of Science ®Google Scholar
• Beckmann R. Wo2012163520): Dual targeting. 2012
   Google Scholar
• Mazor Y, Oganesyan V, Yang C, Hansen A, Wang J, Liu H, Sachsenmeier K, Carlson M, Gadre DV, Borrok MJ, et al. Improving target cell specificity using a novel monovalent bispecific igg design. MAbs 2015; 7(2):377-89; PMID:25621507; http://dx.doi.org/10.1080/19420862.2015.1007816
   PubMed Web of Science ®Google Scholar
• Liu Z, Leng EC, Gunasekaran K, Pentony M, Shen M, Howard M, Stoops J, Manchulenko K, Razinkov V, Liu H, et al. A novel antibody engineering strategy for making monovalent bispecific heterodimeric igg antibodies by electrostatic steering mechanism. J Biol Chem 2015; 290(12):7535-62; PMID:25583986; http://dx.doi.org/10.1074/jbc.M114.620260
   PubMed Web of Science ®Google Scholar
• Wu X, Sereno AJ, Huang F, Lewis SM, Lieu RL, Weldon C, Torres C, Fine C, Batt MA, Fitchett JR, et al. Fab-based bispecific antibody formats with robust biophysical properties and biological activity. MAbs 2015; 7(3):470-82; PMID:25774965; http://dx.doi.org/10.1080/19420862.2015.1022694
   PubMed Web of Science ®Google Scholar
• Lewis SM, Wu X, Pustilnik A, Sereno A, Huang F, Rick HL, Guntas G, Leaver-Fay A, Smith EM, Ho C, et al. Generation of bispecific igg antibodies by structure-based design of an orthogonal fab interface. Nat Biotechnol 2014; 32(2):191-8; PMID:24463572; http://dx.doi.org/10.1038/nbt.2797
   PubMed Web of Science ®Google Scholar
• Kontermann RE, Brinkmann U. Bispecific antibodies. Drug Discov Today 2015; 20(7):838-47; PMID:25728220; http://dx.doi.org/10.1016/j.drudis.2015.02.008
   PubMed Web of Science ®Google Scholar
• Spiess C, Zhai Q, Carter PJ. Alternative molecular formats and therapeutic applications for bispecific antibodies. Mol Immunol 2015; 67(2 Pt A):95-106; PMID:25637431; http://dx.doi.org/10.1016/j.molimm.2015.01.003
   PubMed Web of Science ®Google Scholar
• Grote M, Haas AK, Klein C, Schaefer W, Brinkmann U. Bispecific antibody derivatives based on full-length igg formats. Methods Mol Biol 2012; 901(247-63; PMID:22723106; http://dx.doi.org/10.1007/978-1-61779-931-0_16
   PubMedGoogle Scholar
• Gunasekaran K, Pentony M, Shen M, Garrett L, Forte C, Woodward A, Ng SB, Born T, Retter M, Manchulenko K, et al. Enhancing antibody fc heterodimer formation through electrostatic steering effects: Applications to bispecific molecules and monovalent igg. J Biol Chem 2010; 285(25):19637-46; PMID:20400508; http://dx.doi.org/10.1074/jbc.M110.117382
   PubMed Web of Science ®Google Scholar
• Moore GL, Bautista C, Pong E, Nguyen DH, Jacinto J, Eivazi A, Muchhal US, Karki S, Chu SY, Lazar GA. A novel bispecific antibody format enables simultaneous bivalent and monovalent co-engagement of distinct target antigens. MAbs 2011; 3(6):546-57; PMID:22123055; http://dx.doi.org/10.4161/mabs.3.6.18123
   PubMed Web of Science ®Google Scholar
• Davis JH, Aperlo C, Li Y, Kurosawa E, Lan Y, Lo KM, Huston JS. Seedbodies: Fusion proteins based on strand-exchange engineered domain (seed) ch3 heterodimers in an fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies. Protein Eng Des Sel 2010; 23(4):195-202; PMID:20299542; http://dx.doi.org/10.1093/protein/gzp094
   PubMed Web of Science ®Google Scholar
• Thomas M, Kienast Y, Scheuer W, Bahner M, Kaluza K, Gassner C, Herting F, Brinkmann U, Seeber S, Kavlie A, et al. A novel angiopoietin-2 selective fully human antibody with potent anti-tumoral and anti-angiogenic efficacy and superior side effect profile compared to pan-angiopoietin-1/-2 inhibitors. PLoS One 2013; 8(2):e54923; PMID:23405099; http://dx.doi.org/10.1371/journal.pone.0054923
   PubMed Web of Science ®Google Scholar
• Kienast Y, Klein C, Scheuer W, Raemsch R, Lorenzon E, Bernicke D, Herting F, Yu S, The HH, Martarello L, et al. Ang-2-vegf-a crossmab, a novel bispecific human igg1 antibody blocking vegf-a and ang-2 functions simultaneously, mediates potent antitumor, antiangiogenic, and antimetastatic efficacy. Clin Cancer Res 2013; 19(24):6730-40; PMID:24097868; http://dx.doi.org/10.1158/1078-0432.CCR-13-0081
   PubMed Web of Science ®Google Scholar
• Gassner C, Lipsmeier F, Metzger P, Beck H, Schnueriger A, Regula JT, Moelleken J. Development and validation of a novel spr-based assay principle for bispecific molecules. J Pharm Biomed Anal 2015; 102:144-9; PMID:25277666; http://dx.doi.org/10.1016/j.jpba.2014.09.007
   PubMed Web of Science ®Google Scholar
• Srivastava K, Hu J, Korn C, Savant S, Teichert M, Kapel SS, Jugold M, Besemfelder E, Thomas M, Pasparakis M, et al. Postsurgical adjuvant tumor therapy by combining anti-angiopoietin-2 and metronomic chemotherapy limits metastatic growth. Cancer Cell 2014; 26(6):880-95; PMID:25490450; http://dx.doi.org/10.1016/j.ccell.2014.11.005
   PubMed Web of Science ®Google Scholar
• Bessho H, Wong B, Huang D, Tan J, Ong CK, Iwamura M, Hart S, Dangl M, Thomas M, Teh BT. Effect of ang-2-vegf-a bispecific antibody in renal cell carcinoma. Cancer Invest 2015; 33(8):378-86; PMID:26115098; http://dx.doi.org/10.3109/07357907.2015.1047505
   PubMed Web of Science ®Google Scholar
• Fenn S, Schiller CB, Griese JJ, Duerr H, Imhof-Jung S, Gassner C, Moelleken J, Regula JT, Schaefer W, Thomas M, et al. Crystal structure of an anti-ang2 crossfab demonstrates complete structural and functional integrity of the variable domain. PLoS One 2013; 8(4):e61953; PMID:23613981; http://dx.doi.org/10.1371/journal.pone.0061953
   PubMedGoogle Scholar
• Kloepper J, Riedemann L, Amoozgar Z, Seano G, Susek K, Yu V, Dalvie N, Amelung RL, Datta M, Song JW, et al. Ang-2/vegf bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival. Proc Natl Acad Sci U S A 2016; 113:4476-81; PMID:27044098
   PubMed Web of Science ®Google Scholar
• Hidalgo M, Le Tourneau C, Massard C, Boni V, Calvo E, Albanell J, Taus A, Sablin MP, Varga A, Bahleda R, et al. Results from the first-in-human (fih) phase i study of ro5520985 (rg7221), a novel bispecific human anti-ang-2/anti-vegf-a antibody, administered as an intravenous infusion to patients with advanced solid tumors. J Clin Oncol 2014; 32(15)
   Web of Science ®Google Scholar
• Oaknin A, Floquet A, Le Tourneau C, Ray-Coquard IL, Joly F, Hidalgo M, Leary A, Krieter O, Lahr A, Rossomanno S, et al. Single agent vanucizumab (ro5520985) for platinum (pt)-resistant recurrent ovarian cancer (oc): Results from a single arm extension phase of the phase i fih study. J Clin Oncol 2015; 33(15)
   Web of Science ®Google Scholar
• Otani A, Takagi H, Oh H, Koyama S, Matsumura M, Honda Y. Expressions of angiopoietins and tie2 in human choroidal neovascular membranes. Invest Ophthalmol Vis Sci 1999; 40(9):1912-20; PMID:10440243
   PubMed Web of Science ®Google Scholar
• Takagi H, Koyama S, Seike H, Oh H, Otani A, Matsumura M, Honda Y. Potential role of the angiopoietin/tie2 system in ischemia-induced retinal neovascularization. Invest Ophthalmol Vis Sci 2003; 44(1):393-402; PMID:12506101; http://dx.doi.org/10.1167/iovs.02-0276
   PubMed Web of Science ®Google Scholar
• Rennel ES, Regula JT, Harper SJ, Thomas M, Klein C, Bates DO. A human neutralizing antibody specific to ang-2 inhibits ocular angiogenesis. Microcirculation 2011; 18(7):598-607; PMID:21851472; http://dx.doi.org/10.1111/j.1549-8719.2011.00120.x
   PubMed Web of Science ®Google Scholar
• Zhang F, Zhang J, Liu M, Zhao L, LingHu R, Feng F, Gao X, Jiao S, Hu Y, Yang J. Combating her2-overexpressing breast cancer through induction of calreticulin exposure by tras-permut crossmab. Oncoimmunology 2015; 4(3):e994391; PMID:25949918; http://dx.doi.org/10.4161/2162402X.2014.994391
   PubMedGoogle Scholar
• Zhao L, Xie F, Tong X, Li H, Chen Y, Qian W, Duan S, Zheng J, Zhao Z, Li B, et al. Combating non-hodgkin lymphoma by targeting both cd20 and hla-dr through cd20-243 crossmab. MAbs 2014; 6(3):740-8; PMID:24670986; http://dx.doi.org/10.4161/mabs.28613
   PubMed Web of Science ®Google Scholar
• Zhao L, Tong Q, Qian W, Li B, Zhang D, Fu T, Duan S, Zhang X, Zhao J, Dai J, et al. Eradication of non-hodgkin lymphoma through the induction of tumor-specific t-cell immunity by cd20-flex bifp. Blood 2013; 122(26):4230-6; PMID:24178967; http://dx.doi.org/10.1182/blood-2013-04-496554
   PubMed Web of Science ®Google Scholar
• Asokan M, Rudicell RS, Louder M, McKee K, O'Dell S, Stewart-Jones G, Wang K, Xu L, Chen X, Choe M, et al. Bispecific antibodies targeting different epitopes on the hiv-1 envelope exhibit broad and potent neutralization. J Virol 2015; 89(24):12501-12; PMID:26446600; http://dx.doi.org/10.1128/JVI.02097-15
   PubMed Web of Science ®Google Scholar
• Huang Y, Yu J, Lanzi A, Yao X, Andrews CD, Tsai L, Gajjar M, Sun M, Seaman M, Padte NN, et al. Engineered bispecific antibodies with exquisite hiv-1-neutralizing activity. Cell 2016 June 16; 165(7):1621-1631; PMID:27315479; http://dx.doi.org/10.1016/j.cell.2016.05.024
   PubMed Web of Science ®Google Scholar
• Bispecific Anti-HIV-1 Antibodies with Enhanced Breadth and Potency. Bournazos S, Gazumyan A, Seaman MS, Nussenzweig MC, Ravetch JV. Cell. 2016 Jun 16;165(7):1609-1620. doi:10.1016/j.cell.2016.04.050. PMID: 27315478.
   PubMedGoogle Scholar
• Tung HY, Su YC, Chen BM, Burnouf PA, Huang WC, Chuang KH, Yan YT, Cheng TL, Roffler SR. Selective delivery of pegylated compounds to tumor cells by anti-peg hybrid antibodies. Mol Cancer Ther 2015; 14(6):1317-26; PMID:25852063; http://dx.doi.org/10.1158/1535-7163.MCT-15-0151
   PubMed Web of Science ®Google Scholar
• Lehmann S, Perera R, Grimm HP, Sam J, Colombetti S, Fauti T, Fahrni L, Schaller T, Freimoser-Grundschober A, Zielonka J, et al. In vivo imaging of the activity of cea tcb, a novel t-cell bispecific antibody, reveals specific tumor targeting and fast induction of t-cell mediated tumor killing. Clin Cancer Res 2016 Apr 26; PMID:27117182
   PubMedGoogle Scholar
• Bacac M, Fauti T, Sam J, Colombetti S, Weinzierl T, Ouaret D, Bodmer W, Lehmann S, Hofer T, Hosse RJ, et al. A novel carcinoembryonic antigen t-cell bispecific antibody (cea tcb) for the treatment of solid tumors. Clin Cancer Res 2016 Feb 9; PMID:26861458
   PubMedGoogle Scholar
• Vu MD, Moser S, Delon C, Latzko M, Gianotti R, Luoend R, Friang C, Murr R, Duerner LJ, Weinzierl T, et al. A new class of t-cell bispecific antibodies for the treatment of multiple myeloma, binding to b cell maturation antigen and cd3 and showing potent, specific antitumor activity in myeloma cells and long duration of action in cynomolgus monkeys. Blood 2015; 126(23)
   Web of Science ®Google Scholar
• Seckinger A, Delgado JA, Moreno L, Neuber B, Grab A, Lipp S, Merino J, Vu MD, Strein K, Prosper F, et al. Target expression, preclinical activity and mechanism of action of em801: A novel first-in-class bcma t-cell bispecific antibody for the treatment of multiple myeloma. Blood 2015; 126(23); PMID:NOT_FOUND
   PubMedGoogle Scholar
• Imhof-Jung S, Klein C, Regula J, Schaefer W, Schanzer J. Wo2010145792: Bispecific antigen binding proteins. 2010
   Google Scholar
• Imhof-Jung S, Klein C, Regula J, Schaefer W, Schanzer J. Wo2010145793: Bispecific, tetravalent antigen binding proteins. 2010
   Google Scholar
• Brunker P, Wartha K, Friess T, Grau-Richards S, Waldhauer I, Ferrara Koller C, Weiser B, Majety M, Runza V, Niu H, et al. Rg7386, a novel tetravalent fap-dr5 antibody, effectively triggers fap-dependent, avidity-driven dr5 hyperclustering and tumor cell apoptosis. Mol Cancer Ther 2016; 15:946-57; PMID:27037412
   PubMed Web of Science ®Google Scholar
• Kim JM, Ashkenazi A. Fcgamma receptors enable anticancer action of proapoptotic and immune-modulatory antibodies. J Exp Med 2013; 210(9):1647-51; PMID:23980122; http://dx.doi.org/10.1084/jem.20131625
   PubMed Web of Science ®Google Scholar
• Fischer JA, Hueber AJ, Wilson S, Galm M, Baum W, Kitson C, Auer J, Lorenz SH, Moelleken J, Bader M, et al. Combined inhibition of tumor necrosis factor alpha and interleukin-17 as a therapeutic opportunity in rheumatoid arthritis: Development and characterization of a novel bispecific antibody. Arthritis Rheumatol 2015; 67(1):51-62; PMID:25303306; http://dx.doi.org/10.1002/art.38896
   PubMed Web of Science ®Google Scholar
• Bossenmaier B, Kettenberger H, Klein C, Kuenkele KP, Regula J, Schaefer W, Schwaiger M, Sustmann C. Wo2012116927: Monovalent antigen binding protein. 2012
   Google Scholar
• Bossenmaier B, Kettenberger H, Klein C, Kuenkele KP, Regula J, Schaefer W, Schwaiger M, Sustmann C. Wo2012116926a1: Antigen binding proteins. 2012
   Google Scholar
• Bostrom J, Yu SF, Kan D, Appleton BA, Lee CV, Billeci K, Man W, Peale F, Ross S, Wiesmann C, et al. Variants of the antibody herceptin that interact with her2 and vegf at the antigen binding site. Science 2009; 323(5921):1610-4; PMID:19299620; http://dx.doi.org/10.1126/science.1165480
   PubMed Web of Science ®Google Scholar
• Castoldi F, Hass A, Klein C, Schaefer W, Sustmann C. Wo2013174873a1: Multispecific antibodies. 2013
   Google Scholar
• Brinkmann U, Croasdale R, Hoffmann E, Klein C, Moessner E, Schanzer J, Umana P. Wo2010115589: Trivalent bispecific antibodies. 2010
   Google Scholar
• Metz S, Panke C, Haas AK, Schanzer J, Lau W, Croasdale R, Hoffmann E, Schneider B, Auer J, Gassner C, et al. Bispecific antibody derivatives with restricted binding functionalities that are activated by proteolytic processing. Protein Eng Des Sel 2012; 25(10):571-80; PMID:22976197; http://dx.doi.org/10.1093/protein/gzs064
   PubMed Web of Science ®Google Scholar
• Castoldi R, Ecker V, Wiehle L, Majety M, Busl-Schuller R, Asmussen M, Nopora A, Jucknischke U, Osl F, Kobold S, et al. A novel bispecific egfr/met antibody blocks tumor-promoting phenotypic effects induced by resistance to egfr inhibition and has potent antitumor activity. Oncogene 2013; 32(50):5593-5601; PMID:23812422; http://dx.doi.org/10.1038/onc.2013.245
   PubMed Web of Science ®Google Scholar
• Castoldi R, Jucknischke U, Pradel LP, Arnold E, Klein C, Scheiblich S, Niederfellner G, Sustmann C. Molecular characterization of novel trispecific erbb-cmet-igf1r antibodies and their antigen-binding properties. Protein Eng Des Sel 2012; 25(10):551-9; PMID:22936109; http://dx.doi.org/10.1093/protein/gzs048
   PubMed Web of Science ®Google Scholar
• Schanzer JM, Wartha K, Croasdale R, Moser S, Kunkele KP, Ries C, Scheuer W, Duerr H, Pompiati S, Pollman J, et al. A novel glycoengineered bispecific antibody format for targeted inhibition of epidermal growth factor receptor (egfr) and insulin-like growth factor receptor type i (igf-1r) demonstrating unique molecular properties. J Biol Chem 2014; 289(27):18693-706; PMID:24841203; http://dx.doi.org/10.1074/jbc.M113.528109
   PubMed Web of Science ®Google Scholar
• Croasdale R, Klein C, Schaefer W, Schanzer J. Wo2010136172: Tri- or tetraspecific antibodies. 2010
   Google Scholar
• Hu S, Fu W, Xu W, Yang Y, Cruz M, Berezov SD, Jorissen D, Takeda H, Zhu W. Four-in-one antibodies have superior cancer inhibitory activity against egfr, her2, her3, and vegf through disruption of her/met crosstalk. Cancer Res 2015; 75(1):159-70; PMID:25371409; http://dx.doi.org/10.1158/0008-5472.CAN-14-1670
   PubMed Web of Science ®Google Scholar
• Mirschberger C, Schiller CB, Schraml M, Dimoudis N, Friess T, Gerdes CA, Reiff U, Lifke V, Hoelzlwimmer G, Kolm I, et al. Rg7116, a therapeutic antibody that binds the inactive her3 receptor and is optimized for immune effector activation. Cancer Res 2013; 73(16):5183-94; PMID:23780344; http://dx.doi.org/10.1158/0008-5472.CAN-13-0099
   PubMed Web of Science ®Google Scholar
• Meneses-Lorente G, Friess T, Kolm I, Holzlwimmer G, Bader S, Meille C, Thomas M, Bossenmaier B. Preclinical pharmacokinetics, pharmacodynamics, and efficacy of rg7116: A novel humanized, glycoengineered anti-her3 antibody. Cancer Chemother Pharmacol 2015; 75(4):837-50; PMID:25702049; http://dx.doi.org/10.1007/s00280-015-2697-8
   PubMed Web of Science ®Google Scholar
• Bruenker P, Jaeger C, Klein C, Moessner E, Schaefer W. Wo2015052230a1: Multispecific domain exchanged common variable light chain antibodies. 2015
   Google Scholar
• Bruenker P, Fauti T, Jaeger C, Klein C, Umana P. Wo2014056783a1: Fc-free antibodies comprising two fab fragments and methods of use. 2014
   Google Scholar
• Cho HS, Mason K, Ramyar KX, Stanley AM, Gabelli SB, Denney DW, Jr., Leahy DJ. Structure of the extracellular region of her2 alone and in complex with the herceptin fab. Nature 2003; 421(6924):756-60; PMID:12610629; http://dx.doi.org/10.1038/nature01392
   PubMed Web of Science ®Google Scholar
• Saul FA, Poljak RJ. Crystal structure of human immunoglobulin fragment fab new refined at 2.0 a resolution. Proteins 1992; 14(3):363-71; PMID:1438175; http://dx.doi.org/10.1002/prot.340140305
   PubMed Web of Science ®Google Scholar